Dutch company Vitestro received FDA De Novo authorization on 19 August 2026 for Aletta, the first autonomous blood-draw robot cleared in the United States. Across a trial of more than 1,600 patients the device hit the vein on the first attempt in 94.5% of cases.
Key takeaways
- FDA De Novo authorization dated 19 August 2026, for adults in non-hospital settings
- First-stick success: 94.5% across a trial of more than 1,600 patients
- Three imaging methods: near-infrared, ultrasound and Doppler
- CE Mark since August 2024, European commercial launch planned for 2027
- Phlebotomy workforce turnover: 25% a year, vacancy rate around 10%
How Aletta finds the vein
Aletta does not guess. Every draw runs through a fixed sequence of three imaging methods, the last of which — Doppler?Doppler imaging: An ultrasound technique that measures the speed and direction of blood flow. It distinguishes a vein from an artery, which is a safety precondition for an automated needle insertion. — acts as the safety check.
The sequence of a single blood draw by Aletta
The company stresses one property of the ultrasound layer that matters for treating patients equally.
Ultrasound is skin-tone agnostic.
Luuk Giesen, Chief Medical Officer at Vitestro.
Accuracy on par with a good phlebotomist
The results were published in a peer-reviewed study in Clinical Chemistry. The 94.5% rate held up in patients with obesity and in the elderly — the groups where humans struggle most to find a vein.
Joe El-Khoury, a clinical chemist at Yale, judged the device "definitely as good if not better" than a typical professional.
The route to market took two years longer in the US
| Date | Event |
|---|---|
| May 2024 | Pivotal trial results presented at WorldLab 2024 |
| August 2024 | CE Mark — conformity with the European MDR |
| March 2026 | Series B round: $70 million |
| April 2026 | Peer-reviewed study published in Clinical Chemistry |
| 19 August 2026 | FDA De Novo authorization, announced on 20 August |
| 2027 | Announced European commercial launch |
The bottleneck is staffing, not technology
Turnover among phlebotomists?Phlebotomist: A professional who draws blood for diagnostic testing. In the US this is a distinct medical occupation with its own certification, and one hit by persistently high turnover. runs at 25% a year and vacancies sit at roughly 10%. The deployment model assumes one person supervises machines rather than performing every draw.
Vitestro raised $70 million in a Series B in March 2026 to fund it. The company was founded by Toon Overbeeke and Brian Joseph and is headquartered in Utrecht.
Why it matters
The De Novo pathway?De Novo pathway: An FDA route for devices with no equivalent already on the market. It creates a new classification that later manufacturers can cite under the simpler 510(k) process. itself matters more here than the numbers. No regulatory category existed for this class of device, and now there is a precedent.
That moves autonomous medical robotics out of the demo bracket and into the laboratory-equipment bracket. The brake is no longer the regulator but the reimbursement model and staff willingness to supervise rather than perform.
What's next
- European commercial launch is set for 2027 even though the company obtained its CE Mark back in August 2024
- The FDA authorization covers adults in non-hospital settings only — paediatrics and inpatient wards need a separate filing
- Vitestro has disclosed no pricing and no unit order book, so the pace of US deployment remains unknown
